A study of the Influence of mevalonic acid and its metabolites on the morphology of swiss 3T3 cells.
We used two model systems to investigate the effect of compactin, a competitive inhibitor of beta-hydroxy beta-methylglutarylcoenzyme A reductase, on the shape of Swiss 3T3 cells. We maintained cells in a quiescent state in medium deficient in platelet-derived growth factor (PDGF), or we added PDGF to quiescent cells to initiate traverse through a single cell cycle. In both systems, the cells responded to compactin by acquiring a characteristic rounded shape. Cell rounding seemed to depend on an induced deficiency of mevalonic acid (MVA) since the response could be prevented or reversed by adding MVA to the culture medium. Compactin-induced rounding appeared in PDGF-stimulated cells concomitantly with a compactin-mediated inhibition of DNA synthesis, and both effects had similar sensitivities to exogenous compactin and MVA. However, cell rounding seemed to be unrelated to other, previously observed effects of MVA deficiency. Compactin did not influence the total content of cell cholesterol, and little cholesterol was formed when we added radioactive MVA to round cells to effect shape change reversal. Measurement of the dolichol-dependent glycosylation of cell protein revealed no evidence of dolichol deficiency. In addition, reversal of cell rounding by MVA was not prevented by concentrations of tunicamycin that effectively blocked the incorporation of radioactive mannose into cell protein or by concentrations of cycloheximide that blocked protein synthesis. Taken together, our results suggest a new role for MVA or its products in the maintenance of cell shape.
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000166:cytology*; D002784:Cholesterol / Q000096:biosynthesis; D004247:DNA / Q000096:biosynthesis; D004286:Dolichols / Q000096:biosynthesis; D006133:Growth Substances / Q000494:pharmacology; D008148:Lovastatin / Q000031:analogs & derivatives*; D008798:Mevalonic Acid / Q000172:deficiency / Q000494:pharmacology* / Q000502:physiology; D051379:Mice; D009281:Naphthalenes / Q000494:pharmacology*; D010455:Peptides / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor; D014176:Protein Biosynthesis
D004286:Dolichols; D006133:Growth Substances; D009281:Naphthalenes; D010455:Peptides; D010982:Platelet-Derived Growth Factor; C012258:mevastatin; D004247:DNA; D002784:Cholesterol; D008148:Lovastatin; D008798:Mevalonic Acid